Abstract

Damage-associated molecular patterns (DAMPs) are endogenous molecules activating the immune system upon release from injured cells. Here we show that the IFI16 protein, once freely released in the extracellular milieu of chronically inflamed tissues, can function as a DAMP either alone or upon binding to lipopolysaccharide (LPS). Specifically, using pull-down and saturation binding experiments, we show that IFI16 binds with high affinity to the lipid A moiety of LPS. Remarkably, IFI16 DAMP activity is potentiated upon binding to subtoxic concentrations of strong TLR4-activating LPS variants, as judged by TLR4-MD2/TIRAP/MyD88-dependent IL-6, IL-8 and TNF-α transcriptional activation and release in stimulated monocytes and renal cells. Consistently, using co-immunoprecipitation (co-IP) and surface plasmon resonance (SPR) approaches, we show that IFI16 is a specific TLR4-ligand and that IFI16/LPS complexes display a faster stimulation turnover on TLR4 than LPS alone. Altogether, our findings point to a novel pathomechanism of inflammation involving the formation of multiple complexes between extracellular IFI16 and subtoxic doses of LPS variants, which then signal through TLR4.

Highlights

  • In the absence of stress stimuli, expression of the nuclear IFI16 protein is restricted to hematopoietic cells, vascular endothelial cells and keratinocytes [1]

  • We show that extracellular IFI16 acts as a damage-associated molecular pattern (DAMP), triggering inflammation through Toll-like receptor 4 (TLR4) activation

  • We demonstrate that IFI16 activity is potentiated upon binding to subtoxic concentrations of strong TLR4-activating lipopolysaccharide (LPS) variants, which are known to be present

Read more

Summary

Introduction

In the absence of stress stimuli, expression of the nuclear IFI16 protein is restricted to hematopoietic cells, vascular endothelial cells and keratinocytes [1]. Serum circulating IFI16 protein and its specific autoantibodies have been reported in various autoimmune diseases, including SSc, rheumatoid arthritis (RA), SLE, SS, psoriatic arthritis (PsA) and IBD [6,8,16,17,18,19,20]. Our group and others have reported IFI16 de-localization to the cytoplasm upon viral infection or UVB exposure [8,21,22,23]. Under these conditions, IFI16 is eventually released in the extracellular matrix where it acts as a damage-associated molecular pattern (DAMP), inducing a proinflammatory phenotype [8,24]. The molecular mechanisms underlying the extracellular DAMP activity of IFI16 have yet to be determined

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call